Filing Flows

Filing Flows › Health Care › VivoSim Labs (VIVS)

VivoSim Labs (VIVS) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Aug 12, 2026 · VivoSim Labs (VIVS) Q1 FY27 earnings results →

Q1 FY27 Revenue down 51% year over year to $18K

VivoSim Labs made $18K in Q1 FY27 (-51% Y/Y). Operating margin n/m, net loss $1.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.

Revenue$18K
Year over year-51%
Operating marginn/m
Net earnings−$1.3M
Operating cash flow−$3.2M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $18K in Q1 FY27, down 51% year over year and down 55% from the previous quarter.

Operating costs exceeded revenue by $2.8M, an operating margin of -15327.8%. Total costs fell 6% while revenue fell 51%. The fastest-growing cost line was Research & development (+13%). The quarter ended with a net loss of $1.3M, narrower than the previous quarter's $5.8M loss. Non-operating items added $1.4M, -107% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was −$3.2M. Non-cash charges added back $40K of depreciation and amortization and $91K of share-based compensation. Working capital and other items used $2.0M. Capital expenditures of $23K exceeded it, leaving free cash flow of −$3.2M.

Quarterly history

VivoSim Labs revenue by quarterVivoSim Labs revenue by quarter$24KQ3 FY25$51KQ4 FY25$37KQ1 FY26$28KQ2 FY26$26KQ3 FY26$40KQ4 FY26$18KQ1 FY27
VivoSim Labs net earnings by quarterVivoSim Labs net earnings by quarter−$3.4MQ3 FY25$6.9MQ4 FY25−$2.8MQ1 FY26−$2.5MQ2 FY26−$2.7MQ3 FY26−$5.8MQ4 FY26−$1.3MQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QAug 12, 2026$18K-51%n/m−$1.3M−$3.2M
Q4 FY2610-KJul 14, 2026$40K-22%n/m−$5.8M−$2.2M
Q3 FY2610-QFeb 11, 2026$26K+8%n/m−$2.7M−$2.3M
Q2 FY2610-QNov 6, 2025$28K-7%n/m−$2.5M−$2.4M
Q1 FY2610-QAug 12, 2025$37K-5%n/m−$2.8M−$3.9M
Q4 FY2510-KJun 5, 2025$51K+76%n/m$6.9M−$2.0M
Q3 FY2510-QFeb 19, 2025$24K+380%n/m−$3.4M−$1.8M

Charts

VivoSim Labs: revenue growth, year over year and quarter over quarterVivoSim Labs: revenue growth, year over year and quarter over quarterY/YQ/Q+380%Q3 FY25+76%+112%Q4 FY25-5%-27%Q1 FY26-7%-24%Q2 FY26+8%-7%Q3 FY26-22%+54%Q4 FY26-51%-55%Q1 FY27
Latest (Q1 FY27): Y/Y -51%, Q/Q -55%.
VivoSim Labs: where the cash came from (+) and went (−), TTM to Q1 FY27VivoSim Labs: where the cash came from (+) and went (−), TTM to Q1 FY27Operating cash flow−$10.1MCash drawn (+) / kept (−)$7.4MShares issued$3.0MOther financing−$353KOther investing$94KCapital spending−$23K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
VivoSim Labs: profit against cash, quarter by quarterVivoSim Labs: profit against cash, quarter by quarterNet incomeOperating cash flow−$2.5M−$2.6MQ2 FY25−$3.4M−$1.8MQ3 FY25$6.9M−$2.0MQ4 FY25−$2.8M−$3.9MQ1 FY26−$2.5M−$2.4MQ2 FY26−$2.7M−$2.3MQ3 FY26−$5.8M−$2.2MQ4 FY26−$1.3M−$3.2MQ1 FY27
Latest (Q1 FY27): Net income −$1.3M, Operating cash flow −$3.2M.
VivoSim Labs: diluted shares by fiscal year (split-adjusted)VivoSim Labs: diluted shares by fiscal year (split-adjusted)28MFY2135MFY2235MFY233MFY243MFY253MFY26
-90.6% since FY21: buybacks shrank the count; earlier years scaled for the 2-for-1 split before FY26, 2-for-1 split before FY25.
VivoSim Labs in its industry: growth against margin (76 companies, SIC 2836)VivoSim Labs in its industry: growth against margin (76 companies, SIC 2836)revenue growth, year over year →↑ operating marginmedian +9%median -100%AMGNGILDBIIBMRNANBIXEXELHALOMGTXTECHVIRRGENTARSBCRXALECADMAKRYSIOVATWSTIPSCIMCRVISKVCELADPTNVAXKYMRGLUEIBRXAUTLAGENDNAPLXRXRXFENCCSBRCHRSIVVDCRSPEDITDTILVXRTSTRORGNXCCCCBSEMSCLXACOGTSHASRZNVYGRFDMTLENZALGSXFORELUTFATEOCGNSCTXCRBUCGONDBVTINBXMGXLCTXTCRXDYAIPRMEATRAVitro Biopharma, Inc.HUMARLAYPLURBEAMPROKCRDFAIMVIVS (-51%, -100%)
Biological Products, (No Diagnostic Substances); dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About VivoSim Labs

VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.

In its own words, from its 8-K, filed Aug 6, 2026.

VivoSim Labs against its Biological Products, (No Diagnostic Substances) peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -51% against the peers' median +11%.

CompanyQuarterRevenueY/YOp. margin
VIVS VivoSim LabsQ1 FY27$18K-51%n/m
AMGN AmgenQ3 2026$10.4B+8%35.8%
GILD Gilead SciencesQ3 2026$8.3B+7%41.7%
BIIB BiogenQ3 2026$2.8B+11%-0.3%
MRNA ModernaQ3 2026$1.3B+29%9.9%
NBIX Neurocrine BiosciencesQ3 2026$1.1B+41%29.5%
EXEL ExelixisQ3 2026$659M+10%40.8%
HALO Halozyme TherapeuticsQ3 2026$493M+39%59.8%
MGTX MeiraGTx HoldingsQ2 2026$321M87×76.0%

Source: VivoSim Labs 10-Q on SEC EDGAR · CIK 1497253 · Biological Products, (No Diagnostic Substances)

13F: who owns VIVS and who is buying

Largest holders of VIVS (13F)Largest holders of VIVS (13F)Vanguard Group$40KGeode Capital Management, LLC$28KRenaissance Technologies LLC$20KVanguard Capital Management LLC$16KBlackRock$13KVanguard Fiduciary Trust$7KTower Research Capital LLC$6KSBI Securities$236Larson Financial Group LLC$178Albion Financial$171
Funds' net buying of VIVS by quarter (13F)Funds' net buying of VIVS by quarter (13F)$143K2025-03$65K2025-06$177K2025-09−$153K2025-12−$34K2026-03−$14K2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on VIVS

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare VIVS with

中文版：VivoSim Labs（VIVS）财报

Español · Français